Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Young Shin Cho

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitorsMichael Shultz, Jianmei Fan, Christine Chen, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 InhibitorsYoung Shin Cho, Hayley Angove, Christopher Brain, et al.
Journal of Medicinal Chemistry|June 10, 2011
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitorsMichael D Shultz, Xueying Cao, Christine H Chen, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitorsMichael Shultz, Jianmei Fan, Christine Chen, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 InhibitorsYoung Shin Cho, Hayley Angove, Christopher Brain, et al.
Journal of Medicinal Chemistry|June 10, 2011
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitorsMichael D Shultz, Xueying Cao, Christine H Chen, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Pageof 5